Showing 2241-2250 of 2735 results for "".
- Allergan Aesthetics Launches Program to Elevate the Conversation Around Ethics in Aestheticshttps://modernaesthetics.com/news/allergan-aesthetics-launches-program-to-elevate-the-conversation-around-ethics-in-aesthetics/2473556/Allergan Aesthetics announced the launch of 'Moving the Needle on Ethics,' a collaboration with medical aesthetics experts from around the globe aimed at elevating discussions on ethics in aesthetics. The collection of interviews is designed to highlight the
- Highlights From IMCAS World Congress 2024: 25 years at the Forefront of Medical Aesthetics and Countinghttps://modernaesthetics.com/news/highlights-from-imcas-world-congress-2024-25-years-at-the-forefront-of-medical-aesthetics-and-counting-1/2473561/As a veteran of the International Master Course on Aging Science (IMCAS) for over two decades, IMCAS 2024 was the largest congress to date with over 18,000 attendees in the Palais des Congres. Located in central Paris, we had to navigate a construction zone as workmen were busy getting the city r
- Nordic Pharma Welcomes John P. Fezza, MD, to Medical Advisory Boardhttps://modernaesthetics.com/news/nordic-pharma-welcomes-john-fezza-md-to-medical-advisory-board/2473554/Nordic Pharma, Inc., has announced the appointment of renowned oculoplastic surgeon Dr. John P. Fezza, MD, to its U.S. Medical Advisory Board (MAB), according to a press release. The appointment comes as Nordic Pharma prepares to introduce LACRIFILL® Canalicular Gel, a groundb
- FDA Approves Juvederm Voluma XC for Temple Hollowinghttps://modernaesthetics.com/news/fda-approves-juvederm-voluma-xc-for-temple-hollowing/2473553/Allergan Aesthetics has received FDA approval of Juvederm Voluma XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.[1] The injection is the first and only hyaluronic acid (HA) dermal filler to receive FDA approval
- Letybo (letibotulinumtoxinA-wlbg) Receives FDA Approvalhttps://modernaesthetics.com/news/fda-grants-approval-for-letybo-letibotulinumtoxina-wlbg/2473551/Hugel America, Inc., announced the achievement of a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for its neurotoxin, Letybo. "We are thrilled with the FDA's approval of Letybo. This is a huge achievement for Hugel as we
- Trufacial Touts Survey Showing High Satisfaction with Facial Rejuvenation Systemhttps://modernaesthetics.com/news/trufacial-survery-results/2473550/A market survey of 100 female consumers revealed that 100% of participants found the skin-perfecting TrufacialTM hand-held device not only met their skincare needs, but also exceeded expectations after only
- Cutera Launches AviClear for the Treatment of Acne in UK, Europe and Australiahttps://modernaesthetics.com/news/cutera-launches-aviclear-for-the-treatment-of-acne-in-uk-europe-and-australia/2473548/Cutera announced the international limited commercial release of AviClear, which the company describes as the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. AviClear is now commercially available, on a limited basis, in the UK, Europe, a
- Beauty and Self-Care Brands Announce Rennaï Spotshttps://modernaesthetics.com/news/beauty-and-self-care-brands-announce-rennai-spots/2473546/Rennaï, a new beauty and self-care retail concept in Montreal, announced that luxury global brand Hermes will be joining world-renowned professional-grade skin care brand Dermalogica at its flagship location at Royalmount. The combination of coveted luxury brands, ma
- Tracking Trends in Breast Implant Surgery Techniques From 2005 to 2020https://modernaesthetics.com/news/tracking-trends-in-breast-implant-surgery-techniques-from-2005-to-2020/2473538/Breast implant placement with inframammary incisions increased from 68% to 80%, while use of peri-areolar incisions decreased from 24% to 14% between 2005 and 2020, according to a study in the December 2023 issue of Plastic and Reconstruct
- Exosome X Mitochondrial Technology: Elevai Labs Enters Into Licensing Agreement With Yuva Bioscienceshttps://modernaesthetics.com/news/exosome-x-mitochondrial-technologies-elevai-labs-enters-into-licensing-agreement-with-yuva-biosciences/2473536/Elevai Labs, Inc. signed a licensing agreement with Yuva Biosciences, Inc. to research and develop means to incorporate Yuva Bioscience’s mitochondrial research with ELEVAI’s PREx (Precision Regenerative Exosome Technology) in topical skincare. The potential collab could com